Menu

Fueled By FYR

FYR is revolutionizing the ability to dynamically observe disease and treatment response to produce better biomarkers, trials, drugs and outcomes. FYR’s EV-Omics (EVO) platform leverages its proprietary technology, SPARCs, to enrich for extracellular vesicles from diseased cells and enable assessment of cellular proteins and nucleic acids with just a peripheral blood sample. Utilizing AI-enabled multiomic insights, EVO unravels the complexity of disease mechanisms, thereby informing potential diagnostic and treatment options. The unparalleled view provided by FYR’s multiomic approach can transform personalized patient care, from screening through therapy selection and monitoring.

image description

Collaborators

Our Leadership

  • Chris Booth, Ph.D.

    CEO & Board Member

  • Sarjubhai Patel, Ph.D.

    President & Board Member

  • Katie Havranek, Ph.D., MB (ASCP) CM

    Director, Research & Dev.

  • David Booth

    Chief Operating Officer

  • Brian Conway, MBA

    VP of Operations

  • Adam LaBonte

    VP of Commercial Development

  • Abdallah Elias, MD, FACMG, FAAP, FAAFP​

    Clinical Lab Director

  • Claire Seibold, MS

    Director of Software and Data Analytics

Our Board of Directors

  • Chris Booth, Ph.D.

    CEO & Board Member

  • Sarjubhai Patel, Ph.D.

    President & Board Member

  • Michael Goguen

    Board Member

  • Chris Howlett

    Board Member

Our Scientific Advisors

  • Mark Adams, Ph.D.

    Advisor

  • Andrew Hill, Ph.D.

    Advisor

  • Niall Lennon, Ph.D.

    Advisor

  • Kirk Tanner, Ph.D.

    Advisor

  • Ryan Walters, Ph.D.

    Advisor

Our Clinical Advisors

  • Priya Kumthekar, MD

    Advisor
image description

Sparking Innovation Together

Have we sparked your interest in partnering with us? We fuel new relationships, collaborations, and strategic partnerships. Let’s kindle the next generation of innovation together.

Contact us